London
Roots Analysis has announced the addition
of
Over
time, extensive R&D on the potential health benefits of cannabis, have
enabled medical researchers to identify a number of pharmacologically active
ingredients that offer clinical benefit, minus the addictive properties of the
crude substance. Currently, several stakeholders in the pharmaceutical industry
are actively engaged in the efforts to develop leads based on natural and
synthetic derivatives of cannabinoids.
To order this 250+ page report, which
features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key Market
Insights
Over 175
drugs targeting the endocannabinoid system are currently under development
Most cannabinoid-based
drug candidates are being developed to target the CB1 and CB2 receptors. Nearly
45% of such drugs are presently being investigated in clinical trials, while
50% are in the preclinical / discovery phase. Majority
of these therapies (60%) are designed for oral administration.
More than
60 companies claim to develop endocannabinoid system targeted therapeutics
Post
2010, there has been a significant rise in the number of companies working in
this domain; such companies represent 63% of the total number of players. Majority
of the firms engaged in this domain (74%) are based in North America, followed
by those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America
(2%).
Partnership
activity has grown at an annualized rate of 35%, between 2017 and 2019
The maximum
number of partnerships were observed in 2019 within this segment of the
pharmaceutical industry. Majority of these agreements were reported to have been
inked for research purposes (20%). In addition, more than 35 merger /
acquisition deal were signed between 2016 and 2020; service / facility
expansion emerged as the most prominent key value drivers for such agreements.
Close to 600
grants were awarded for supporting research on endocannabinoid system targeted
therapeutics, since 2016
Almost 45%
of the total amount awarded in the form of grants, was under the R01 (in
support of health-related research and development based on the mission of
the NIH) mechanism. Further, grants (394) worth USD 147 million were
awarded to research projects related to endocannabinoid system.
At
present, therapies intended for the treatment of neurological disorders represent
the majority share of the overall endocannabinoid system targeted therapeutics
market
Most of the therapies targeting neurological
disorders are intended for the treatment of epilepsy. In addition to neurological
disorders, therapies intended for autoimmune disorders, cancer and genetic
disorders are likely to capture significant market opportunity in the foreseen
future.
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/316/request-sample.html
For additional details, please
visit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
or email sales@rootsanalysis.com
You may also be interested in the
following titles:
2.
3.
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
